Discovery of novel immunoevasins from HHV-6 and -7
从 HHV-6 和 -7 中发现新型免疫逃避蛋白
基本信息
- 批准号:7359231
- 负责人:
- 金额:$ 22.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-06-26 至 2010-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinity ChromatographyAntigen PresentationAntigen-Presenting CellsAntigensAutoimmune DiseasesBindingCell Adhesion MoleculesCell Culture SystemCell LineCell surfaceCellsCellular MembraneCellular biologyCytomegalovirusCytotoxic T-LymphocytesDetectionDiseaseDown-RegulationDuctalEncephalitisExcisionExpression LibraryGoalsHerpesviridaeHistocompatibility Antigens Class IHuman Herpesvirus 6Human Herpesvirus 7ImmuneImmune responseImmune systemImmunocompromised HostIndividualInfectionKnowledgeLeadLifeLigandsMembrane ProteinsMolecularNatural Killer CellsOpen Reading FramesOpportunistic InfectionsPathogenesisPopulationSalivary GlandsSimplexvirusSurfaceTestingTransplant RecipientsViralViral ProteinsVirusVirus Diseasescell killingnovelpermissivenessreceptorresearch studyresponsesalivary celltherapeutic target
项目摘要
DESCRIPTION (provided by applicant): HHV-6 and -7 are two closely related 2-herpesviruses that infect over 90% of the population. These opportunistic viruses do not cause serious illness in healthy people, but in immunocompromised individuals, these viruses can reactivate and cause life-threatening encephalitis and CMV disease. Like all other herpesviruses, HHV-6 and -7 persist or remain latent in their hosts throughout life. In so doing, herpesviruses have evolved numerous strategies to escape detection by the immune system. Notably, all of the herpesviruses thus far examined interfere with viral antigen presentation to cytotoxic T lymphocytes (CTLs) by removing class I MHC molecules from the infected cell surface. Clearly, since the herpesviruses have evolved such an extensive array of mechanisms to remove class I MHC molecules from the cell surface, this strategy serves them well. However, when Natural Killer (NK) cells detect an absence of class I MHC molecules on the surface of a cell (i.e., "missing self"), they become activated to kill that cell. The focus of this application is to discover how HHV-6 and -7 evade the NK and CTL cell responses to viral infection. Several strategies will be employed to identify novel viral immunoevasins that allow HHV-6/-7 infected cells to escape detection: 1) we will explore the function of open reading frames within HHV-6 and -7 that have obvious homology to immune molecules. 2) We will screen HHV-6 and -7- infected antigen-presenting cells for the surface downregulation of candidate cellular membrane proteins involved in the initiation of a cytolytic response against an infected cell. The long term goal of this project is to understand the mechanisms by which HHV-6 and -7 evade detection by the immune system. Revelation of the mechanisms by which these opportunistic viruses evade the immune system will not only contribute to the understanding of these viruses and their pathogenesis, but also to the understanding of basic underlying principles of cell biology. Ultimately, the knowledge gained from understanding how these molecules function to subvert the immune response may lead to the identification of potential therapeutic targets for the treatment of these opportunistic infections, as well as for the treatment of autoimmune disorders.
描述(由申请方提供):HHV-6和HHV-7是两种密切相关的2-疱疹病毒,感染超过90%的人群。这些机会性病毒在健康人群中不会引起严重疾病,但在免疫功能低下的个体中,这些病毒可以重新激活并引起危及生命的脑炎和CMV疾病。与所有其他疱疹病毒一样,HHV-6和HHV-7在宿主体内持续存在或潜伏终生。在这样做的过程中,疱疹病毒已经进化出许多策略来逃避免疫系统的检测。值得注意的是,迄今为止检查的所有疱疹病毒通过从感染的细胞表面去除I类MHC分子来干扰病毒抗原呈递给细胞毒性T淋巴细胞(CTL)。显然,由于疱疹病毒已经进化出了如此广泛的一系列机制来从细胞表面去除I类MHC分子,这种策略很好地为它们服务。然而,当自然杀伤(NK)细胞检测到细胞表面上不存在I类MHC分子时(即,“失去自我”),它们被激活杀死那个细胞。本申请的重点是发现HHV-6和HHV-7如何逃避NK和CTL细胞对病毒感染的应答。将采用几种策略来鉴定允许HHV-6/-7感染的细胞逃避检测的新型病毒免疫逃避素:1)我们将探索与免疫分子具有明显同源性的HHV-6和-7内的开放阅读框的功能。2)我们将筛选HHV-6和HHV-7感染的抗原呈递细胞,寻找参与启动针对感染细胞的溶细胞反应的候选细胞膜蛋白的表面下调。该项目的长期目标是了解HHV-6和HHV-7逃避免疫系统检测的机制。揭示这些机会性病毒逃避免疫系统的机制不仅有助于理解这些病毒及其发病机制,而且有助于理解细胞生物学的基本原理。最终,从了解这些分子如何发挥作用来破坏免疫反应中获得的知识可能会导致识别用于治疗这些机会性感染以及治疗自身免疫性疾病的潜在治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AMY W HUDSON其他文献
AMY W HUDSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AMY W HUDSON', 18)}}的其他基金
Subversion of lysosomal trafficking by HHV-7 U21
HHV-7 U21 颠覆溶酶体贩运
- 批准号:
9706283 - 财政年份:2016
- 资助金额:
$ 22.42万 - 项目类别:
Immune evasion in a humanized mouse model of HHV-6 infection
HHV-6 感染人源化小鼠模型中的免疫逃避
- 批准号:
8500953 - 财政年份:2013
- 资助金额:
$ 22.42万 - 项目类别:
Discovery of novel immunoevasins from HHV-6 and -7
从 HHV-6 和 -7 中发现新型免疫逃避蛋白
- 批准号:
7644445 - 财政年份:2008
- 资助金额:
$ 22.42万 - 项目类别:
Mechanisms of immune evasion by HHV-6 and HHV-7 U21
HHV-6 和 HHV-7 U21 的免疫逃避机制
- 批准号:
7319325 - 财政年份:2007
- 资助金额:
$ 22.42万 - 项目类别:
Mechanisms of immune evasion by HHV-6 and HHV-7 U21
HHV-6 和 HHV-7 U21 的免疫逃避机制
- 批准号:
8092661 - 财政年份:2007
- 资助金额:
$ 22.42万 - 项目类别:
Mechanisms of immune evasion by HHV-6 and HHV-7 U21
HHV-6 和 HHV-7 U21 的免疫逃避机制
- 批准号:
7898957 - 财政年份:2007
- 资助金额:
$ 22.42万 - 项目类别:
Mechanisms of immune evasion by HHV-6 and HHV-7 U21
HHV-6 和 HHV-7 U21 的免疫逃避机制
- 批准号:
7646378 - 财政年份:2007
- 资助金额:
$ 22.42万 - 项目类别:
Mechanisms of immune evasion by HHV-6 and HHV-7 U21
HHV-6 和 HHV-7 U21 的免疫逃避机制
- 批准号:
7448432 - 财政年份:2007
- 资助金额:
$ 22.42万 - 项目类别:
相似海外基金
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10506915 - 财政年份:2021
- 资助金额:
$ 22.42万 - 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10325006 - 财政年份:2021
- 资助金额:
$ 22.42万 - 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
- 批准号:
1746198 - 财政年份:2018
- 资助金额:
$ 22.42万 - 项目类别:
Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
- 批准号:
512537-2017 - 财政年份:2017
- 资助金额:
$ 22.42万 - 项目类别:
University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
- 批准号:
1404605 - 财政年份:2014
- 资助金额:
$ 22.42万 - 项目类别:
Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
- 批准号:
1263713 - 财政年份:2013
- 资助金额:
$ 22.42万 - 项目类别:
Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
- 批准号:
425749-2012 - 财政年份:2012
- 资助金额:
$ 22.42万 - 项目类别:
Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
- 批准号:
1159886 - 财政年份:2012
- 资助金额:
$ 22.42万 - 项目类别:
Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
- 批准号:
19560760 - 财政年份:2007
- 资助金额:
$ 22.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
- 批准号:
234753-2000 - 财政年份:2003
- 资助金额:
$ 22.42万 - 项目类别:
Collaborative Research and Development Grants